POST-TRANSCRIPTIONAL REGULATION OF UPAR EXPRESSION

Information

  • Research Project
  • 6142544
  • ApplicationId
    6142544
  • Core Project Number
    R43CA086637
  • Full Project Number
    1R43CA086637-01
  • Serial Number
    86637
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/1/2000 - 24 years ago
  • Project End Date
    3/31/2001 - 23 years ago
  • Program Officer Name
    FORRY-SCHAUDIES, SUZANNE L.
  • Budget Start Date
    4/1/2000 - 24 years ago
  • Budget End Date
    3/31/2001 - 23 years ago
  • Fiscal Year
    2000
  • Support Year
    1
  • Suffix
  • Award Notice Date
    3/10/2000 - 24 years ago

POST-TRANSCRIPTIONAL REGULATION OF UPAR EXPRESSION

Metastasis of tumor cells is a key process in the progression of cancer. This process is tightly regulated by a small number of proteins essential to the intravasion of tumor tissue and subsequent neovascularization of the tumor, and additionally the invasion of non-cancerous tissue by tumor cells shed from the parent body. Up regulation of the expression of uPAR has been shown to significantly contribute to these processes. Conversely, antisense mediated down regulation of uPAR significantly inhibits both neovascularization and invasion by metastatic cells. Previous results show that the expression of uPAR is post-transcriptionally regulated through an undefined mechanism involving uncharacterized proteins interacting with two distinct regions of the mRNA uPAR. This grant will find and characterize peptide mimetics of the endogenous binding proteins, as a prelude to establishing a high throughput screening program to identify small molecules drugs capable of modulating this regulatory process. Structurally defined peptide libraries will be constructed on polystyrene beads employing a mix and split protocol. A solid phase screening process will be employed to find peptide mimetics, which will subsequently be characterized in the solution phase. PROPOSED COMMERCIAL APPLICATIONS: Identification of peptide mimetics of the endogenous uPAR mRNA binding proteins will allow for the development of a high throughput screening program to identify a new class of anti-cancer drugs which elicit their effects through a novel post-transcriptional mechanism.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    99499
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:99499\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MESSAGE PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    MALVERN
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    19355
  • Organization District
    UNITED STATES